A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
Clinical trial NCT03430297 · COMPLETED
Trial details
- NCT number
- NCT03430297
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-02
- Primary completion
- 2023-07-12
- Enrollment
- 256
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.